Heparin-associated thrombocytopenia in the neurosurgical patient.
Although thrombocytopenia occurs in approximately 10% of medical patients who receive heparin, this complication has not been described in neurosurgical patients. We report the clinical course of two patients who in the immediate postoperative period developed heparin-associated thrombocytopenia that resulted in significant morbidity. In these two cases, the origin of the heparin was in "flush" solutions used to maintain the patency of indwelling vascular catheters and was infused at a dose of 250 to 500 units/day. The minimal daily dose previously reported to result in thrombocytopenia is 9000 units/day administered in divided doses subcutaneously. The case reports indicate that heparin in "flush" solutions should be considered as a cause for unexpected thrombocytopenia and that platelet counts should be monitored in patients receiving heparin in any amount.
D000328:Adult; D001932:Brain Neoplasms / Q000097:blood / Q000601:surgery*; D005260:Female; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008579:Meningioma / Q000097:blood / Q000601:surgery*; D008875:Middle Aged; D009442:Neurilemmoma / Q000097:blood / Q000601:surgery*; D011183:Postoperative Complications; D013921:Thrombocytopenia / Q000097:blood / Q000139:chemically induced*
D006493:Heparin